Systematic Review Examines GLP-1s Drugs’ Effectiveness and Safety in Patients Without Diabetes
A systematic review of randomized clinical trials involving about 15 500 participants without diabetes found that all 12 of the identified glucagon-like peptide-1 (GLP-1) receptor agonists led to decreased body mass, waist circumference, and blood pressure. Of the 3 commercially available agents—liraglutide, semaglutide, and tirzepatide—the latter resulted in the greatest weight loss, with participants reporting up to an 18% change in body weight after nearly 17 months.
A systematic review of randomized clinical trials involving about 15 500 participants without diabetes found that all 12 of the identified glucagon-like peptide-1 (GLP-1) receptor agonists led to decreased body mass, waist circumference, and blood pressure. Of the 3 commercially available agents—liraglutide, semaglutide, and tirzepatide—the latter resulted in the greatest weight loss, with participants reporting up to an 18% change in body weight after nearly 17 months.
